These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 34085706)

  • 1. Synthetic resin acid derivatives selectively open the hK
    Ottosson NE; Silverå Ejneby M; Wu X; Estrada-Mondragón A; Nilsson M; Karlsson U; Schupp M; Rognant S; Jepps TA; Konradsson P; Elinder F
    Epilepsia; 2021 Jul; 62(7):1744-1758. PubMed ID: 34085706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional and behavioral signatures of Kv7 activator drug subtypes.
    Kanyo R; Wang CK; Locskai LF; Li J; Allison WT; Kurata HT
    Epilepsia; 2020 Aug; 61(8):1678-1690. PubMed ID: 32652600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine.
    Main MJ; Cryan JE; Dupere JR; Cox B; Clare JJ; Burbidge SA
    Mol Pharmacol; 2000 Aug; 58(2):253-62. PubMed ID: 10908292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KCNQ3 is the principal target of retigabine in CA1 and subicular excitatory neurons.
    Varghese N; Lauritano A; Taglialatela M; Tzingounis AV
    J Neurophysiol; 2021 Apr; 125(4):1440-1449. PubMed ID: 33729829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIP2 mediates functional coupling and pharmacology of neuronal KCNQ channels.
    Kim RY; Pless SA; Kurata HT
    Proc Natl Acad Sci U S A; 2017 Nov; 114(45):E9702-E9711. PubMed ID: 29078287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequence determinants of subtype-specific actions of KCNQ channel openers.
    Wang AW; Yang R; Kurata HT
    J Physiol; 2017 Feb; 595(3):663-676. PubMed ID: 27506413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atomic basis for therapeutic activation of neuronal potassium channels.
    Kim RY; Yau MC; Galpin JD; Seebohm G; Ahern CA; Pless SA; Kurata HT
    Nat Commun; 2015 Sep; 6():8116. PubMed ID: 26333338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One drug-sensitive subunit is sufficient for a near-maximal retigabine effect in KCNQ channels.
    Yau MC; Kim RY; Wang CK; Li J; Ammar T; Yang RY; Pless SA; Kurata HT
    J Gen Physiol; 2018 Oct; 150(10):1421-1431. PubMed ID: 30166314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retigabine holds KV7 channels open and stabilizes the resting potential.
    Corbin-Leftwich A; Mossadeq SM; Ha J; Ruchala I; Le AH; Villalba-Galea CA
    J Gen Physiol; 2016 Mar; 147(3):229-41. PubMed ID: 26880756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retigabine, a Kv7.2/Kv7.3-Channel Opener, Attenuates Drug-Induced Seizures in Knock-In Mice Harboring Kcnq2 Mutations.
    Ihara Y; Tomonoh Y; Deshimaru M; Zhang B; Uchida T; Ishii A; Hirose S
    PLoS One; 2016; 11(2):e0150095. PubMed ID: 26910900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics of KCNQ channel activation in 2 potassium channelopathy mouse models of epilepsy.
    Vanhoof-Villalba SL; Gautier NM; Mishra V; Glasscock E
    Epilepsia; 2018 Feb; 59(2):358-368. PubMed ID: 29265344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pore- and voltage sensor-targeted KCNQ openers have distinct state-dependent actions.
    Wang CK; Lamothe SM; Wang AW; Yang RY; Kurata HT
    J Gen Physiol; 2018 Dec; 150(12):1722-1734. PubMed ID: 30373787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the KCNQ potassium channel opener retigabine on single KCNQ2/3 channels expressed in CHO cells.
    Tatulian L; Brown DA
    J Physiol; 2003 May; 549(Pt 1):57-63. PubMed ID: 12702739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Sensorless Pore Module of Voltage-gated K+ Channel Family 7 Embodies the Target Site for the Anticonvulsant Retigabine.
    Syeda R; Santos JS; Montal M
    J Biol Chem; 2016 Feb; 291(6):2931-7. PubMed ID: 26627826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining endocannabinoids with retigabine for enhanced M-channel effect and improved KV7 subtype selectivity.
    Larsson JE; Karlsson U; Wu X; Liin SI
    J Gen Physiol; 2020 Aug; 152(8):. PubMed ID: 32365171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The novel dual-mechanism Kv7 potassium channel/TSPO receptor activator GRT-X is more effective than the Kv7 channel opener retigabine in the 6-Hz refractory seizure mouse model.
    Bloms-Funke P; Bankstahl M; Bankstahl J; Kneip C; Schröder W; Löscher W
    Neuropharmacology; 2022 Feb; 203():108884. PubMed ID: 34785163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits.
    Rundfeldt C; Netzer R
    Neurosci Lett; 2000 Mar; 282(1-2):73-6. PubMed ID: 10713399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Refinement of the binding site and mode of action of the anticonvulsant Retigabine on KCNQ K+ channels.
    Lange W; Geissendörfer J; Schenzer A; Grötzinger J; Seebohm G; Friedrich T; Schwake M
    Mol Pharmacol; 2009 Feb; 75(2):272-80. PubMed ID: 19015229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dominant-negative effects of KCNQ2 mutations are associated with epileptic encephalopathy.
    Orhan G; Bock M; Schepers D; Ilina EI; Reichel SN; Löffler H; Jezutkovic N; Weckhuysen S; Mandelstam S; Suls A; Danker T; Guenther E; Scheffer IE; De Jonghe P; Lerche H; Maljevic S
    Ann Neurol; 2014 Mar; 75(3):382-94. PubMed ID: 24318194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a retigabine derivative that inhibits KCNQ2 potassium channels.
    Hu HN; Zhou PZ; Chen F; Li M; Nan FJ; Gao ZB
    Acta Pharmacol Sin; 2013 Oct; 34(10):1359-66. PubMed ID: 23933653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.